par Tabernero, Josep;Van Cutsem, Eric;Díaz-Rubio, Eduardo;Cervantes, Andrés;Humblet, Yves;André, Thierry;Van Laethem, Jean-Luc ;Soulié, Patrick;Casado, Esther;Verslype, Chris;Valera, Javier Sastre;Tortora, Giampaolo;Ciardiello, Fortunato;Kisker, Oliver;de Gramont, Aimery
Référence Journal of clinical oncology, 25, 33, page (5225-5232)
Publication Publié, 2007-11
Référence Journal of clinical oncology, 25, 33, page (5225-5232)
Publication Publié, 2007-11
Article révisé par les pairs
Résumé : | This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX-4]) in the first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC). |